Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 437

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 437
---
59 |         1 |   2023 |
| Total                          |         17,261 |    |       -83 |        |         17,334 |        53 |        |         12,556 |        90 |        |

(a) Includes forward sales with a notional amount of $ 3,615million expiring in 2025 , designated as a hedge of Sanofi’s net investment in Bioverativ. As of

December 31, 2024 , the fair value of these forward contracts represented a liability of € 88million ; the opposite entry was recognized in "Other

comprehensive income", with the impact on financial income and expense being immaterial.

(b) Includes forward purchases with a notional amount of $ 1,000million expiring in 2025 , designated as a fair value hedge of the exposure of $ 1,000million

of bond issues to fluctuations in the EUR/USD spot rate. As of December 31, 2024 , the fair value of the contracts was an asset of € 75million , the

opposite entry for € 0.2million of which was debited to “Other comprehensive income” under the cost of hedging accounting treatment.

| SANOFIFORM 20-F2024 | F-77 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

The table below shows interest rate hedging instruments in place as of December 31, 2024 :

|                                       | Notional amounts by expiry date as of December 31,2024 |      |      |      |      |              |       |           | Of whichdesignated asfair value hedges |           | Of which designated ascash flow hedges |           |                             |
| (€ million)                           |                                                   2025 | 2026 | 2027 | 2028 | 2029 | 2030andlater | Total | Fairvalue |                         Notionalamount | Fairvalue | Notionalamount                         | Fairvalue | Of whichrecognizedin equity |
| Interest rate swaps                   |                                                        |      |      |      |      |              |       |           |                                        |           |                                        |           |                             |
| pay capitalized SOFR USD/receive1.03% |                                                      — |    — |    — |  483 |    — | —            |   483 |       -47 |                                    483 |       -47 | —                                      | —         | —                           |
| pay